Herpes Simplex Virus 2 Clinical Trial
Official title:
HerpeSelect® Express Rapid Test Study Protocol Sexually Active Adult Population
This study is designed to compare the performance of the Focus Diagnostics' HerpeSelect® Express, a Herpes Simplex Virus 2 Rapid Test, to a currently marketed device. The intent is to show the rapid test device is comparable to the currently marketed device. HerpeSelect® Express is a rapid test intended for qualitatively detecting the presence or absence of human IgG class antibodies to herpes simplex virus type 2 (HSV-2) in human whole blood (capillary).
The objective of this study is to establish the performance characteristics of the Focus
Diagnostics (Focus) HerpeSelect® Express based on comparison to the Focus Diagnostics'
HerpeSelect® 2 ELISA IgG (K021486). The Focus HerpeSelect® 2 ELISA IgG device is intended
for qualitatively detecting the presence or absence of human IgG class antibodies to HSV-2
in human sera. Positive samples in either the HerpeSelect® 2 ELISA IgG or HerpeSelect®
Express will be tested in the HerpeSelect® Immunoblot (K000238).
This external study along with in-house analytical studies will demonstrate the efficacy of
the HerpeSelect® Express Rapid Test device as an aid in screening for pregnant women or
sexually active adults as in the presumptive diagnosis of HSV-2 infection for point-of-care
testing sites as well as hospital/clinics and reference laboratories. Independent sites in
the Southeastern, Western, Eastern, and Pacific Northwestern U.S. will test subjects with
the HerpeSelect® Express Rapid Test. Sera from those patients will be tested at Focus
Diagnostics Reference Laboratory in the HerpeSelect® 2 ELISA IgG. Discrepants between
HerpeSelect® Express Rapid Test and HerpeSelect® 2 ELISA IgG may be tested in the
HerpeSelect® Immunoblot IgG assay.
Test subjects will be from three patient populations: 375 sexually active adults, 375
pregnant women, and 100 low prevalence adults. Two samples types will be collected from each
subject: capillary whole blood and serum. These samples types will be tested with both the
HerpeSelect® Express Rapid Test and HerpeSelect® 2 ELISA IgG.
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02571166 -
HSV529 Vaccine in HSV-2 Seropositive Adults
|
Phase 1 |